GlassScriptPhysician profile
Brent M Jones
NPI 1063708550
$2,054.54
in general payments reported to CMS, 2019-2025
22 companies · $935 in 2025
The $935 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.75 · 2021: $38.26 · 2022: $13.21 · 2023: $182 · 2024: $825 · 2025: $935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,942.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $410.70 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $291.14 | 2023-2025 | |
| Lilly USA, LLC | $250.85 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $148.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $135.68 | 2022-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $122.82 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $71.78 | 2023-2025 | Rexulti, Abilify Maintena |
| Phathom Pharmaceuticals, INC. | $71.72 | 2024-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $66.68 | 2024-2025 | Gemtesa |
| Supernus Pharmaceuticals, INC. | $58.11 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $56.51 | 2024 | |
| Verona Pharma, INC. | $53.55 | 2025 | Ohtuvayre |
| Kerecis Limited | $52.69 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Glaxosmithkline, LLC. | $50.76 | 2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $50.66 | 2024-2025 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $32.17 | 2019-2024 | Xarelto |
| Abbott Laboratories | $30.70 | 2024 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $29.28 | 2024 | Eliquis, Camzyos |
| Braeburn INC. | $22.09 | 2025 | Brixadi |
| Lundbeck LLC | $20.08 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.09 | 2023 | Tradjenta, Jardiance |
| Aimmune Therapeutics, INC. | $13.93 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brent Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.